![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DHX57 |
Gene summary for DHX57 |
![]() |
Gene information | Species | Human | Gene symbol | DHX57 | Gene ID | 90957 |
Gene name | DExH-box helicase 57 | |
Gene Alias | DDX57 | |
Cytomap | 2p22.1 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q6P158 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
90957 | DHX57 | HCC1_Meng | Human | Liver | HCC | 2.45e-39 | 1.93e-02 | 0.0246 |
90957 | DHX57 | HCC2_Meng | Human | Liver | HCC | 4.12e-09 | 4.62e-03 | 0.0107 |
90957 | DHX57 | HCC2 | Human | Liver | HCC | 3.92e-02 | 1.36e+00 | 0.5341 |
90957 | DHX57 | HCC5 | Human | Liver | HCC | 2.37e-13 | 4.90e-01 | 0.4932 |
90957 | DHX57 | S014 | Human | Liver | HCC | 8.58e-04 | 2.70e-01 | 0.2254 |
90957 | DHX57 | S015 | Human | Liver | HCC | 4.40e-04 | 3.43e-01 | 0.2375 |
90957 | DHX57 | S016 | Human | Liver | HCC | 4.78e-10 | 3.82e-01 | 0.2243 |
90957 | DHX57 | S027 | Human | Liver | HCC | 1.29e-06 | 5.05e-01 | 0.2446 |
90957 | DHX57 | S029 | Human | Liver | HCC | 1.10e-04 | 3.21e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DHX57 | SNV | Missense_Mutation | c.1385C>A | p.Ser462Tyr | p.S462Y | Q6P158 | protein_coding | tolerated(0.07) | benign(0.341) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
DHX57 | SNV | Missense_Mutation | c.1027C>A | p.Leu343Ile | p.L343I | Q6P158 | protein_coding | tolerated(0.14) | probably_damaging(0.932) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
DHX57 | SNV | Missense_Mutation | c.406G>A | p.Glu136Lys | p.E136K | Q6P158 | protein_coding | tolerated(0.1) | benign(0.214) | TCGA-EO-A1Y5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response | |
DHX57 | SNV | Missense_Mutation | novel | c.2210C>T | p.Ala737Val | p.A737V | Q6P158 | protein_coding | deleterious(0.05) | benign(0.313) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DHX57 | SNV | Missense_Mutation | c.8C>A | p.Ser3Tyr | p.S3Y | Q6P158 | protein_coding | deleterious_low_confidence(0) | benign(0.133) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
DHX57 | SNV | Missense_Mutation | novel | c.3508N>G | p.Leu1170Val | p.L1170V | Q6P158 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DHX57 | SNV | Missense_Mutation | c.1022N>A | p.Ser341Tyr | p.S341Y | Q6P158 | protein_coding | deleterious(0.01) | possibly_damaging(0.908) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
DHX57 | SNV | Missense_Mutation | rs771694437 | c.2612C>A | p.Ser871Tyr | p.S871Y | Q6P158 | protein_coding | deleterious(0.05) | benign(0.012) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
DHX57 | SNV | Missense_Mutation | novel | c.3512N>T | p.Ser1171Leu | p.S1171L | Q6P158 | protein_coding | tolerated(0.27) | possibly_damaging(0.681) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DHX57 | SNV | Missense_Mutation | novel | c.3368C>T | p.Ala1123Val | p.A1123V | Q6P158 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-EY-A1GO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |